Kadi Ann Bryan, MD
Urology · Corvallis, ORNPI 1659530442
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,625 of the $3,919 with a category attached, or 67.0%. 29 manufacturers reported payments, led by Procept Biorobotics Corporation at 29.3% of the total. 2024 is the largest year on record at $1,642, 4.8 times the $341 reported in 2019.
Across 122 payments — averaging $32.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$1K
- AbbVie$464
- Astellas Pharma US Inc$451
- Intuitive Surgical$299
- Medtronic$264
- Pfizer$206
- plus $1K from 23 others
What the payments were for
- Travel & lodging$1,08328%
- Food & beverage$2,62567%
- Education$2115%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 5 | $1,147 |
| AbbVie | 22 | $464 |
| Astellas Pharma US Inc | 20 | $451 |
| Intuitive Surgical | 5 | $299 |
| Medtronic(2 entities) | 5 | $264 |
| Pfizer | 12 | $206 |
| Coloplast | 1 | $129 |
| Ferring Pharmaceuticals Inc. | 9 | $123 |
| Boston Scientific | 7 | $112 |
| Tolmar, Inc. | 2 | $69 |
| Sumitomo Pharma America, Inc. | 3 | $66 |
| Johnson & Johnson | 2 | $63 |
| 180 Medical, Inc. | 2 | $59 |
| Myovant Sciences Inc. | 3 | $57 |
| Endo Pharmaceuticals Inc. | 4 | $57 |
| Dendreon Pharmaceuticals LLC | 2 | $42 |
| Myriad Genetic Laboratories, Inc. | 3 | $41 |
| Travere Therapeutics, Inc. | 3 | $39 |
| Amgen | 2 | $34 |
| Teleflex LLC | 1 | $30 |
| Abbott | 1 | $25 |
| Sanofi | 1 | $24 |
| Merck | 1 | $20 |
| Immunitybio, Inc. | 1 | $19 |
| Urogen Pharma, Inc. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Baxter Healthcare | 1 | $15 |
| Ambu Inc. | 1 | $13 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AQUABEAM SYSTEM$1,003
- INTERSTIM$156
- TITAN$129
How this compares
$3,919 in reported general payments places this provider in the 70th percentile of 153 urology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 36 | $96,716 |
| MyrbetriqMirabegron | 34 | $24,409 |
| GemtesaVibegron | 13 | $6,869 |
| Tamsulosin Hcl | 387 | $6,116 |
| Potassium Citrate ErPotassium Citrate | 23 | $3,874 |
| Silodosin | 32 | $2,543 |
| Tolterodine Tartrate ErTolterodine Tartrate | 19 | $1,967 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 89 | $1,818 |
| Methenamine Hippurate | 12 | $1,270 |
| Cephalexin | 146 | $761 |
| NitrofurantoinNitrofurantoin Macrocrystal | 32 | $593 |
| Finasteride | 48 | $362 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 67 | $306 |
| Ciprofloxacin Hcl | 23 | $172 |
| Tramadol Hcl | 102 | $154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $66 | $103,58549 claims |
| Astellas Pharma US IncMyrbetriq | $451 | $24,40934 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 153 urology providers in Oregon.
Other urology in Corvallis
- Robert LaciakCorvallis$17K
- Layron LongCorvallis$15K
- Bryce AllioCorvallis$5K
- Bryan MehlhaffSpringfield$1M
- Lance MarrPortland$323K
- Matt AshleyBend$212K
- da David JiangPortland$65K
- Kim ThaiMedford$57K
- Kevin KrughoffSpringfield$54K
- Kyle GillisClackamas$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.